Drug General Information
Drug ID	D0MJ2H
Former ID	DIB012531
Drug Name	KD-7040
Indication	Pain [ICD9: 338, 356.0, 356.8,780; ICD10:G64, G90.0, R52, G89]		Phase 2	[522187]
Company	Kalypsys Inc
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Nitric oxide synthase, inducible	Target Info	Inhibitor	[550174]
BioCyc Pathway	Citrulline-nitric oxide cycle
KEGG Pathway	Arginine biosynthesis
	Arginine and proline metabolism
	Metabolic pathways
	Calcium signaling pathway
	HIF-1 signaling pathway
	Peroxisome
	Salmonella infection
	Pertussis
	Leishmaniasis
	Chagas disease (American trypanosomiasis)
	Toxoplasmosis
	Amoebiasis
	Tuberculosis
	Pathways in cancer
	Small cell lung cancer
NetPath Pathway	IL1 Signaling Pathway
	IL2 Signaling Pathway
Pathway Interaction Database	IL12-mediated signaling events
	Alpha9 beta1 integrin signaling events
	ATF-2 transcription factor network
	IL23-mediated signaling events
	Signaling mediated by p38-alpha and p38-beta
	HIF-1-alpha transcription factor network
Reactome	ROS production in response to bacteria
	Nitric oxide stimulates guanylate cyclase
WikiPathways	Type II interferon signaling (IFNG)
	Spinal Cord Injury
	AGE/RAGE pathway
	Effects of Nitric Oxide
References
Ref 522187	ClinicalTrials.gov (NCT00576108) A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN). U.S. National Institutes of Health.
Ref 550174	WO patent application no. 2014,0214,08, Method for treating cancer by anticancer agent co-administration.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.